These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 20634671)
1. Interstitial lung disease associated with azacitidine use: a case report. Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671 [TBL] [Abstract][Full Text] [Related]
2. Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome. Hueser CN; Patel AJ Pharmacotherapy; 2007 Dec; 27(12):1759-62. PubMed ID: 18041893 [TBL] [Abstract][Full Text] [Related]
3. Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome. Nair GB; Charles M; Ogden L; Spiegler P Respir Care; 2012 Apr; 57(4):631-3. PubMed ID: 22005027 [TBL] [Abstract][Full Text] [Related]
4. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome. Adams CD; Szumita PM; Baroletti SA; Lilly CM Pharmacotherapy; 2005 May; 25(5):765-8. PubMed ID: 15899739 [TBL] [Abstract][Full Text] [Related]
6. Is there an association between 5-azacitidine and ototoxicity? Malik A; Misbah S; Spaccavento C; Yudelman I J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015 [No Abstract] [Full Text] [Related]
7. Azacitidine-Induced Interstitial Pneumonitis. Verriere B; Ferreira V; Denis E; Zahreddine K; Deletie E; Quinsat D; Re D Am J Ther; 2016; 23(5):e1205-8. PubMed ID: 26371947 [TBL] [Abstract][Full Text] [Related]
8. Azacitidine-induced cryptogenic organizing pneumonia: a case report and review of the literature. Alnimer Y; Salah S; Abuqayas B; Alrabi K J Med Case Rep; 2016 Jan; 10():15. PubMed ID: 26791087 [TBL] [Abstract][Full Text] [Related]
9. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Voso MT; Breccia M; Lunghi M; Poloni A; Niscola P; Finelli C; Bari A; Musto P; Zambello R; Fianchi L; Alimena G; Leone G Eur J Haematol; 2013 Apr; 90(4):345-8. PubMed ID: 23336938 [TBL] [Abstract][Full Text] [Related]
10. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Santini V Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445 [TBL] [Abstract][Full Text] [Related]
11. Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan. Hayashi M; Takayasu H; Tada M; Yamazaki Y; Tateno H; Tazawa S; Wakabayashi A; Iwasaki T; Tsuchiya Y; Yamashita J; Takeda N; Tomita S; Mori H; Kokubu F Intern Med; 2012; 51(17):2411-5. PubMed ID: 22975559 [TBL] [Abstract][Full Text] [Related]
12. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220 [TBL] [Abstract][Full Text] [Related]
13. Atraumatic splenic rupture in patients with myelodysplastic syndromes: report of a case occurred during treatment with 5-azacitidine and review of the literature. Forghieri F; Morselli M; Leonardi G; Potenza L; Bonacorsi G; Coluccio V; Paolini A; Maccaferri M; Colaci E; Fantuzzi V; Bigliardi S; Zaldini P; Riva G; Barozzi P; Leonardi L; Rossi A; Marasca R; Narni F; Luppi M Leuk Res; 2012 Mar; 36(3):e52-6. PubMed ID: 22172466 [No Abstract] [Full Text] [Related]
14. Azacitidine-Induced Pericarditis: A Case Series. Newman M; Malla M; Gojo I Pharmacotherapy; 2016 Apr; 36(4):443-8. PubMed ID: 26940554 [TBL] [Abstract][Full Text] [Related]
15. Interstitial pneumonitis--An important differential diagnosis for pulmonary sepsis in haematology patients. Pillai AR; Sadik W; Jones PA; Thachil J Leuk Res; 2012 Jan; 36(1):e39-40. PubMed ID: 21996561 [No Abstract] [Full Text] [Related]
16. Azacitidine-associated Sweet's syndrome. Trickett HB; Cumpston A; Craig M Am J Health Syst Pharm; 2012 May; 69(10):869-71. PubMed ID: 22555082 [TBL] [Abstract][Full Text] [Related]
17. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017 [TBL] [Abstract][Full Text] [Related]
18. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R; Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554 [TBL] [Abstract][Full Text] [Related]
19. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA; J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040 [TBL] [Abstract][Full Text] [Related]
20. Decitabine. Gore SD; Jones C; Kirkpatrick P Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522 [No Abstract] [Full Text] [Related] [Next] [New Search]